Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
15.84
-0.43 (-2.64%)
At close: Feb 18, 2026, 4:00 PM EST
15.87
+0.03 (0.19%)
After-hours: Feb 18, 2026, 7:59 PM EST
Hims & Hers Health Revenue
Hims & Hers Health had revenue of $598.98M in the quarter ending September 30, 2025, with 49.16% growth. This brings the company's revenue in the last twelve months to $2.21B, up 78.02% year-over-year. In the year 2024, Hims & Hers Health had annual revenue of $1.48B with 69.33% growth.
Revenue (ttm)
$2.21B
Revenue Growth
+78.02%
P/S Ratio
1.63
Revenue / Employee
$1,350,616
Employees
1,637
Market Cap
3.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.48B | 604.51M | 69.33% |
| Dec 31, 2023 | 872.00M | 345.08M | 65.49% |
| Dec 31, 2022 | 526.92M | 255.04M | 93.81% |
| Dec 31, 2021 | 271.88M | 123.12M | 82.77% |
| Dec 31, 2020 | 148.76M | 66.20M | 80.18% |
| Dec 31, 2019 | 82.56M | 55.88M | 209.45% |
| Dec 31, 2018 | 26.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.03B |
| Perrigo Company | 4.28B |
| Amneal Pharmaceuticals | 2.93B |
| Lantheus Holdings | 1.53B |
| Alkermes | 1.52B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| Supernus Pharmaceuticals | 681.54M |
HIMS News
- 15 hours ago - HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 16 hours ago - Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings - Seeking Alpha
- 1 day ago - 3 Once-In-A-Decade REIT Opportunities To Win Big - Seeking Alpha
- 5 days ago - Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More - Benzinga
- 5 days ago - Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows - Reuters
- 5 days ago - A Historic Opportunity For Dividend Investors To Win Big - Seeking Alpha
- 5 days ago - US could take action including fines against Hims after brief Wegovy copy launch - Reuters
- 7 days ago - HIMS Selloff Creates De-Risked Entry - Seeking Alpha